key: cord-0943461-zusobnrd
authors: Choe, Michelle; Martinez, Caridad; Krance, Robert; Doherty, Erin
title: Acute exacerbation of graft‐versus‐host disease following SARS‐CoV2 infection after hematopoietic stem cell transplant in two pediatric patients
date: 2022-03-16
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.29661
sha: c2779c87957e44906016f997d902911a2a4732fb
doc_id: 943461
cord_uid: zusobnrd

nan

days after stem cell infusion, at which time the patient developed diarrhea. Infectious workup was negative, and symptoms improved after a single dose of basiliximab and 3 days of IV steroids. Subsequently, oral steroids were successfully weaned off over 3 months as his gastrointestinal (GI) symptoms resolved, and the patient was clinically diagnosed with stage 1 gut GVHD.

On day +122, the patient tested positive for SARS-CoV2 by RT-PCR obtained for screening. He remained asymptomatic and subsequently did not receive any viral-directed therapy. However, about 1 month afterwards, the patient developed worsening rash and diarrhea as well as hematochezia. A full infectious workup was negative. HSCT. Furthermore, we note that patient 2 experienced a less severe course of GVH after receiving SARS-CoV2-directed therapy. In contrast, patient 1 did not receive SARS-CoV2-directed therapy and developed severe acute exacerbation of skin and lower GI GVHD, as well as new onset liver GVHD prior to his untimely death.

The authors recognize that there are many confounding factors that played a role in these two patients' clinical course, namely, the source of HSCT: patient 1 received a haploidentical transplant while patient

State-of-the-art acute and chronic GVHD treatment

The role of regulatory T cells in the biology of graft versus host disease

Prevention and treatment of acute graftversus-host disease in children, adolescents, and young adults

Human herpesvirus-6B reactivation is a risk factor for grades II to IV acute graft-versus-host disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis

Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease

Human herpesvirus-6 reactivation and acute graft-versus-host disease

Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus 2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica

Coronavirus disease 2019 3 months after hematopoietic stem cell transplant: a pediatric case report

Severe coronavirus disease 2019 infection in an adolescent patient after hematopoietic stem cell transplantation

COVID-19 disease in New York City pediatric hematology and oncology patients

COVID-19 in pediatric hematopoietic stem cell transplantation: the experience of Spanish Group of Transplant (GETMON/GETH). Pediatr Blood Cancer

Risk factors for graft-versushost disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide

Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatr Blood Cancer

Current allogeneic hematopoietic stem cell transplantation for pediatric acute lymphocytic leukemia: success, failure and future perspectives-a single-center experience

Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for hodgkin lymphoma

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia